Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events
نویسندگان
چکیده
منابع مشابه
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk reduction compared with aspirin alone. However, a systematic review of all trials of antiplatelet agents by the Antithrombotic Trialists' Collaboration sho...
متن کاملDipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
BACKGROUND AND PURPOSE Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results. We performed a meta-analysis using individual patient data from relevant randomized controlled trials. METHODS Randomized controlled trials involving dipyridamole in pa...
متن کاملAntiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy.
BACKGROUND Antiplatelet drugs are effective and safe in a wide variety of patients at high risk of vascular ischaemic events. Among patients undergoing vascular surgical procedures, these agents significantly reduce the risk of graft or native vessel occlusion. In this context we wished to examine their effects in patients after carotid endarterectomy (CEA). OBJECTIVES The objective of this r...
متن کاملCochrane review: dipyridamole for preventing major vascular events in patients with vascular disease.
BACKGROUND Patients enrolled in clinical trials after nondisabling cerebral ischemia have an annual risk of vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction) of 4% to 11%. Aspirin reduces the incidence by 13%. Many trials in patients presenting with vascular disease investigated the efficacy of (addition of) dipyridamole in secondary prevention...
متن کاملThienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
BACKGROUND Aspirin is the most widely studied and prescribed antiplatelet agent for preventing serious vascular events, reducing the odds of such events among high vascular risk patients by about a quarter. Thienopyridine derivatives inhibit platelet activation by a different mechanism and so may be more effective. OBJECTIVES To determine the effectiveness and safety of thienopyridine derivat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2005
ISSN: 0039-2499,1524-4628
DOI: 10.1161/01.str.0000149621.95215.ea